ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
As the biotech markets turned bullish the sector’s ups and downs continued.
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
Imbruvica faces challenges on multiple fronts.
Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?